Using a recent patient case from my practice, I describe how I am incorporating new selective RET inhibitors such as selpercatinib into managing patients with RET fusion–positive NSCLC.
My take on how selective RET inhibitors are changing the standard of care in advanced thyroid cancer.
Here are my thoughts on what patients need to know about biomarker testing and targeted therapies for lung and thyroid cancers.
Read expert answers to key questions asked by healthcare professionals during a series of live webinars focused on the optimal use of selective RET inhibitors in the treatment of advanced cancers with RET alterations, including how to differentiate between these agents and what to do after progression on them.
For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.